Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5b60af10f691ccb2e5b07e45bb332e9 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-02 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-46 |
filingDate |
2006-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ffec0914558e0fd7306643a381611f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c03a59c22d14de9a11c636cd127592f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67fd8683c41cdd614bca188475919d65 |
publicationDate |
2022-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2902872-T3 |
titleOfInvention |
Supplemented matrices for bone fracture repair |
abstract |
A formulation comprising (i) a peptide selected from the group consisting of PTH and a PTH fusion peptide; (ii) a granular material comprising a mixture of tricalcium phosphate and hydroxyapatite; and (iii) a composition capable of forming a fibrin matrix under physiological conditions comprising a fibrinogen precursor component and a thrombin precursor component, where the PTH or PTH fusion peptide is present in a concentration range between 0.4 to 2 mg/ mL of fibrin matrix or matrix-forming component precursor, provided that a concentration of 0.4 mg/mL of fibrin matrix or matrix-forming component precursor is not included. |
priorityDate |
2005-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |